이글벳

044960KOSDAQ기타 전문 도매업

51.5 / 100

Reference Date: 2026-04-13

Financial Score25.0 / 40

News Sentiment12.5 / 25

Momentum4.0 / 20

Disclosure10.0 / 15

AI Analysis: ROE significantly exceeds the industry average but Revenue metrics are weak. Slightly down 2.9% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Eglvet is a company specializing in the manufacturing and import of animal pharmaceuticals, leveraging the growth of the livestock industry both domestically and internationally. Its key products include nutritional supplements, antibiotics, and vaccines, with active expansion into overseas markets such as Africa, the Middle East, and Southeast Asia. The company is also exploring research opportunities in the growing pet pharmaceutical market.

Number of Employees

110people

Average Salary

48.3M KRW

Score Calculation Basis

Detailed Financial Score

PER

12.26Industry Average 15.635.0Point

In line with industry avg

PBR

0.93Industry Average 0.632.5Point

Higher than industry avg (caution)

ROE

7.85Industry Average 2.097.0Point

3.8x industry avg (excellent)

Debt Ratio

6.70Industry Average 7.874.0Point

In line with industry avg

Trend 2023~20256.5 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲0.7% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲13.6% (2-year basis)

ROE Trend

3.0 / 4

Avg ROE 7.5% (improving, 3yr)

Detailed News Sentiment

3 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (9%, downtrend)

Current 3,825Won52-week high 4,90052-week low 3,715

1-month return2.0Point

1m -2.92% (slight drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-25
Neutral정기주주총회결과2026-03-25
Neutral사업보고서 (2025.12)2026-03-17
Neutral감사보고서제출2026-03-17